Back to search results

Autologous Blood Patch for Prolonged Air Leak After Lung Cancer Surgery

This study is testing if an Autologous Blood Patch (ABP) can help prevent prolonged air leaks (PAL) after lung cancer surgery. An ABP involves taking a small amount of your own blood and putting it into your chest tube. You might be eligible if you've had surgery for non-small cell lung cancer and still have an air leak on the third day after your operation. The study wants to see if ABP reduces the time you stay in the hospital and if you need to be readmitted within 30 days. This study is currently enrolling patients in the United States and Canada.

Study design
This is a multi-institutional randomized, controlled trial with 60 participants per group. You would either receive the Autologous Blood Patch or standard care, as decided by your surgeon.
What's involved
If you have an air leak on the third day after surgery, you would be asked to participate. If randomized to the ABP group, 60-100 ml of your blood would be drawn and put into your chest tube on day 3 and possibly day 4. You will also complete a questionnaire in person or over the phone.
Compensation
Not stated in the trial record.
Follow-up
The study will track your hospital stay and any readmissions for up to 30 days after your surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04954625

Prolonged Air Leak (PAL) Autologous Blood Patch Intervention Trial

Enrolling by Invitation
NAAges 18+InterventionalTreatment
Rush University Medical Center
~60 participants
Updated 2025-10-10 on ClinicalTrials.gov
What's tested:Autologous Blood PatchStandard of Care (per Physician)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Prolonged Air Leak >5 days
Measured over Within 30 Days
+4 more outcomes measured

Conditions

Lung Cancer

Explore related trials

Lung Non-Small Cell CarcinomaProlonged Air Leak

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Christopher Seder, MD · PRINCIPAL_INVESTIGATOR · Rush University Medical Center
  • Sebastien Gilbert, MD · STUDY_DIRECTOR · University of Ottawa

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients who underwent elective wedge resection, segmentectomy, lobectomy, or bilobectomy for suspected non-small cell lung cancer
Patients that have reviewed and signed the Informed Consent Form, had an opportunity to ask questions, and consent to have their de-identified data included in the study
Patients who have an air leak on the morning of postoperative Day 3
Age ≥18 years old

Exclusion

Patients who undergo pneumonectomy, sleeve lobectomy, chest wall or diaphragm resection, or bilateral procedures.
Age \< 18 years old
Women who are pregnant

What this trial measures

  • Prolonged Air Leak >5 daysWithin 30 Days

    Definition of prolonged air leak: air leak present at 5 days or greater

  • Hospital Length of StayWithin 30 Days

    Number of days patient was admitted inpatient

  • Readmission within 30 daysWithin 30 Days

    Determination of whether the patient was readmitted after discharge within 30 days.

  • In hospital mortalityWithin 30 Days

    Survival status while inpatient.

  • 30-day MortalityWithin 30 Days

    Survival status within 30 days consent.